Implanet: Convocation of a New Extraordinary General Shareholders’ Meeting on June 25, 2019

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:

IMPLANET (Euronext Growth: ALIMP, FR0010458729, eligible for
PEA-PME equity savings plans) (Paris:ALIMP) (OTCQX:IMPZY), a medical
technology company specializing in vertebral and knee-surgery implants,
informs its shareholders that its Ordinary General Meeting was held on
Tuesday 11 June at 2 p.m. at the company’s registered office in
Martillac.

All the resolutions of the Ordinary General Meeting have been adopted.

However, the Extraordinary General Shareholders’ Meeting could not
validly deliberate due to lack of quorum. A new Extraordinary General
Shareholders’ Meeting has been called to deliberate on the same agenda
and will be held on June 25, 2019 at 02:00 pm at the Company’s
registered office,
located Allée F. Magendie – Technopole Bordeaux
Montesquieu – 33650 Martillac – France.

A notice of the second meeting will be published on June 14, 2019 in the
BALO and posted on Implanet’s website.

Implanet’s shareholders’s participation is decisive to obtain the
quorum necessary to hold this Extraordinary General Meeting and vote on
the company’s resolutions.

The vote of shareholders who voted by absentee voting at the first
General Meeting remains valid and counted for the Extraordinary General
Meeting on second notice.

The shareholders can vote:

  • by internet via the Votaccess service (reopened on
    14.06.2019),
  • by absentee voting,
  • by proxy voting,
  • or attend physically the General Meeting

A guide contained in a Letter To Shareholders – May, 2019 outlines how
to vote, and in particular how to vote from your internet banking
interface
(only in French). You can download it here.
It was also posted on Implanet’s website. The shareholders can also
contact the Investor Relations team by email for any question concerning
the ways of voting: implanet@newcap.eu

The documents related to the General Meeting are available on request
from Implanet, or can be consulted on the Company’s website (https://www.Implanet-invest.com/assemblee-generale).

About Implanet
Founded in 2007, Implanet is a medical
technology company that manufactures high-quality implants for
orthopedic surgery. Its flagship product, the Jazz® latest-generation
implant, aims to treat spinal pathologies requiring vertebral fusion
surgery Implanet’s tried-and-tested orthopedic platform, which is based
on perfect control over the traceability of its products, provides it
with a proven ability to promote this innovation. Protected by four
families of international patents, JAZZ® has obtained 510(k) regulatory
clearance from the Food and Drug Administration (FDA) in the United
States and the CE mark and the Anvisa authorization in Brazil. Implanet
employs 38 staff and recorded 2018 sales of €6.7 million. For further
information, please visit www.Implanet.com.
Based near Bordeaux in France, Implanet established a US subsidiary in
Boston in 2013. Implanet is listed on Euronext™ Growth market in Paris.
The Company would like to remind that the table for monitoring the
equity line (BEOCABSA, OCA, BSA) and the number of shares outstanding,
is available on its website: http://www.implanet-invest.com/suivi-des-actions-80

Contacts

IMPLANET
Ludovic Lastennet, Directeur Général
David
Dieumegard, Directeur Financier
Tél. : 05 57 99 55 55
investors@Implanet.com

NewCap
Relations Investisseurs
Sandrine Boussard-Gallien
Tél.
: 01 44 71 94 94
Implanet@newcap.eu

NewCap
Relations Médias
Nicolas Merigeau
Tél. : 01 44 71
94 94
Implanet@newcap.eu

Staff

Recent Posts

FinThrive Introduces Agentic AI at HFMA 2025 to Help Customers Transform Healthcare Revenue Cycle Management Performance

Company to also highlight advancements in denials and underpayments management and speak to the measurable…

8 hours ago

FinThrive Debuts Denials and Underpayments Analyzer, a Unified Solution for Denials and Underpayments, at HFMA 2025

Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility…

8 hours ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction…

11 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project as Federal Support for Blockchain Grows

Dr. Anosh Ahmed repurposes West Side warehouse into blockchain innovation center, targeting 250+ jobs and…

11 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy Shift

Dr. Anosh Ahmed converts vacant West Side warehouse into blockchain innovation hub, creating 250+ jobs…

11 hours ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits…

11 hours ago